20080031.TNBC
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A6R9-01A-21R-A32P-07 | — | A | 0.939 |
| 2 | TCGA-AN-A0FN-01A-11R-A034-07 | — | A | 0.916 |
| 3 | f22cfa82-a346-4fed-bc81-21a29bf990ee | — | — | 0.915 |
| 4 | C3N-02923 | — | cohortMD2 | 0.914 |
| 5 | BSR_10_0229_A4_S93 | — | D | 0.912 |
| 6 | SRR12202441 | — | — | 0.911 |
| 7 | c277dab0-361f-4aa6-96b1-522a6e556ae1 | — | — | 0.910 |
| 8 | 20120155.TNBC | — | D | 0.907 |
| 9 | ec054d40-e5b8-496a-8c99-5e7f88f2cf37 | — | — | 0.906 |
| 10 | 20020022.TNBC | — | D | 0.905 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.570 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.520 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.510 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.500 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.490 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.450 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.450 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.440 | Inavolisib | — uncovered |
| COMPLEMENT | 0.420 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.420 | Inavolisib | — uncovered |
| COAGULATION | 0.410 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.410 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.400 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.400 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.380 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.360 | Idelalisib | — uncovered |
| MYOGENESIS | 0.310 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.240 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.220 | Temsirolimus | — uncovered |